ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: PP11 • ACR Convergence 2022

    Exercise as a Supportive Treatment for My Ankylosing Spondylitis

    Sara King-Dowling, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are often caught in a paradox as they experience mobility challenges, but long periods of immobility cause increased…
  • Abstract Number: PP26 • ACR Convergence 2022

    Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life

    Catherine Ames1, Courtney Wells2 and Kristine Carandang1, 1Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 2University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…
  • Abstract Number: PP15 • ACR Convergence 2022

    Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic

    Laura Genoves, Arthritis Foundation, Bainbridge Island, WA

    Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
  • Abstract Number: PP24 • ACR Convergence 2022

    Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp

    Kaye Anderson1, Kristine Carandang2 and Courtney Wells3, 1Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, 2Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 3University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
  • Abstract Number: 1926 • ACR Convergence 2022

    Analysis of New Patient Referrals to a Large Pediatric Rheumatology Clinic

    Daniel Reiff, Melissa Mannion, Emily Smitherman, Matthew Stoll, Peter Weiser and Randy Cron, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Large pediatric rheumatology centers receive hundreds of yearly referrals with a wide variety of complaints and diagnoses. The amount of referrals received can lead…
  • Abstract Number: 2130 • ACR Convergence 2022

    Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study

    Petros P. Sfikakis1, Dimitrios Vassilopoulos2, Gkikas Katsifis3, Georgios Vosvotekas4, Theodoros Dimitroulas5, Argyro Repa6, Grigorios Sakellariou7, THEODORA SIMOPOULOU8, Athanasios Georgountzos9, Andreas Bounas10, Panagiotis Georgiou11, Evangelia Mole12, Evangelia Kataxaki13, Stamatis Nick Liossis14, Evangelos Theodorou15, Christina Antoniadou16, EVANGELOS THEOTIKOS17, PANAYIOTIS VLACHOYIANNOPOULOS18, THEODORA MARKATSELI19, Angeliki Kekki20, NIKOLAOS ANTONAKOPOULOS21 and Dimitrios Boumpas22, 1Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 2Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, 3Naval Hospital of Athens, Athens, Greece, 4Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, 54th Department of Internal medicine, Hippokration Hospital, School of medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, 6Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Crete, Greece, 7Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece, Thessaloniki, Greece, 8Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece, Larissa, Larisa, Greece, 9General Hospital of Athens G. Gennimatas, Athens, Greece, 10Olympion private General Clinic of Patras, Patras, Greece;, Patra, Akhaia, Greece, 11Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, PATRA, Akhaia, Greece, 12Department of Rheumatology, KAT General Hospital of Attica, Athens, Greece, 13Rheumatology Unit, Thriasio General Hospital of Elefsina, Magoula, Greece, 14Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece, Patras, Akhaia, Greece, 15Rheumatology Clinic 251 Hellenic Air Force Hospital, Athens, Greece, 16First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, 17Rheumatology Department, Asklepieion Voulas General Hospital, Athens, Greece, 18Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, 19Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, 20Genesis Pharma SA, Halandri, Greece, 21Genesis Pharma SA, Chalandri, Greece, 224th Department of Internal Medicine, "Attikon" University Hospital, Athens, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Background/Purpose: Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) approved for psoriatic arthritis (PsA). Few clinical studies assessing treatment regimens in PsA have focused…
  • Abstract Number: 2263 • ACR Convergence 2022

    Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis

    Luke Springer1, Kelsey Collins2, Huimin Yan2, Ying Hu3, Farshid Guilak2, Samuel Wickline4, Hua Pan2 and Christine Pham2, 1Washington University School of Medicine, St. Louis, MO, 2Washington University School of Medicine, Saint Louis, MO, 3Washington University, Saint Louis, MO, 4University of South Florida, Tampa, FL

    Background/Purpose: Osteoarthritis (OA) represents the most common form of arthritis and is a major cause of morbidity in the aging population. Post-traumatic OA (PTOA) is…
  • Abstract Number: 1784 • ACR Convergence 2022

    Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study

    Kathryn Bacon1, David Felson1, S. Reza Jafarzadeh2, Vijaya Kolachalama2, Jeffrey Hausdorff3, Eran Gazit4, Joshua Stefanik5, Patrick Corrigan6, Neil Segal7, Cora E. Lewis8, Michael Nevitt9 and Deepak Kumar1, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Tel Aviv University, Tel Aviv, Israel, 4Tel Aviv Suarasky Medical Center, Tel Aviv, Israel, 5Northeastern University, Boston, MA, 6Saint Louis University, St. Louis, MO, 7University of Kansas, Kansas City, KS, 8University of Alabama at Birmingham, Birmingham, AL, 9University of California at San Francisco, Orinda, CA

    Background/Purpose: Altered gait is related to pathogenesis of knee osteoarthritis (OA). For people with knee OA, in addition to pain, declines in physical function are…
  • Abstract Number: 2215 • ACR Convergence 2022

    Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis

    Daniel Solomon1, Jon Giles2, Katherine Liao1, Paul Ridker1, Pamela Rist1, Robert Glynn1, Rachel Broderick3, Fengxin Lu1, Meredith Murray1, Kathleen Vanni1, Leah Santacroce1, Shady Abohashem4, Philip Robson5, Zahi Fayad6, Venkatesh Mani5, Ahmed Tawakol4 and Joan Bathon7, 1Brigham and Women's Hospital, Boston, MA, 2Columbia University, New York, NY, 3Columbia University, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Icahn School of Medicine at Mount Sinai, New York, NY, 6Mount Sinai, New York, NY, 7Columbia University Medical Center, New York, NY

    Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…
  • Abstract Number: PP03 • ACR Convergence 2022

    To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records

    Ida Hakkarinen, Greenbelt, MD

    Background/Purpose: In November 1999, the Institute of Medicine issued a press release announcing publication of To Err is Human: Building a Safer Health System (Kohn…
  • Abstract Number: 2238 • ACR Convergence 2022

    Performance of the 2016 ACR/EULAR Myositis Response Criteria in Adult Dermatomyositis and Polymyositis Therapeutic Trials and Consensus Profiles

    Didem Saygin1, Hanna Kim2, Christian Douglas3, Brian Erman3, Jesse Wilkerson3, john mcgrath3, Chester Oddis4, Ingrid Lundberg5, Anthony Amato6, Ignacio Garcia-De La Torre7, Hector Chinoy8, David Fiorentino9, Lorinda Chung9, Yeong-Wook Song10, Katalin Danko11, Frederick Miller12, Nicola Ruperto13, Jiří Vencovský14, Rohit Aggarwal15 and Lisa G Rider12, 1University of Chicago, Chicago, IL, 2Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, 3Social and Scientific Systems, Inc., Durham, NC, 4University of Pittsburgh, Pittsburgh, PA, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 6Harvard University, Boston, MA, 7Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, 8The University of Manchester, Sale, United Kingdom, 9Stanford University, Stanford, CA, 10Seoul National University, Seoul, Republic of Korea, 11*Deceased, Debrecen, Hungary, 12Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, 13IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, 14Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 15Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The ACR/EULAR myositis response criteria (MRC) were developed as a composite continuous measure (Total Improvement Score (TIS)) using absolute percent changes (abs%) in 6…
  • Abstract Number: 2160 • ACR Convergence 2022

    The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients

    Henriette Didriksen1, Øyvind Molberg2, Adi Mehta3, Suzana Jordan4, Håvard Fretheim3, Einar Gude3, Thor Ueland3, Cathrine Brunborg3, Vyacheslav Palchevskiy5, Torhild Garen3, Øyvind Midtvedt3, Arne Andreassen3, Fridtjof Lund-Johansen3, Oliver Distler4, John Belperio5 and Anna-Maria Hoffmann-Vold3, 1Oslo University Hospital, Moss, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
  • Abstract Number: 2152 • ACR Convergence 2022

    Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis

    Nicoletta Luciano1, Elisa Barone2, Enrico Brunetta1, Maria De Santis3, Angela Ceribelli4, Marta Caprioli5, Giacomo Maria Guidelli1, Arianna Sonaglia1, Daniela Renna6, Francesca Motta7, Natasa Isailovic7, Matteo Vecellio3 and Carlo Selmi8, 1IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, 2IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Lombardia, Italy, 3Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, 4Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, 5IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, 6IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Milano, Italy, 7Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Italy, 8Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy

    Background/Purpose: The management of patients with psoriasis and psoriatic artrhitis (PsA) has been recently enriched and has thus become more challenging by the wide armamentarium…
  • Abstract Number: 2154 • ACR Convergence 2022

    An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin

    Elizabeth Bundschuh1, Rebecca Fine2, Miruna Carnaru3, Sanchit Kumar4, Francis Perry Wilson2, Alyssa Williams1, Shannon Teaw4, Ian Odell4 and Monique Hinchcliff5, 1Yale University, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3Hartford Healthcare Medical Group, Rocky Hill, CT, 4Yale University School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

    Background/Purpose: Receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) and others including PDGFRs, FGFRs, and VEGFRs are implicated in systemic sclerosis (SSc)…
  • Abstract Number: 1785 • ACR Convergence 2022

    PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort

    Susan Bartlett1, orit schieir2, Marie-France Valois2, Janet Pope3, Louis Bessette4, Gilles Boire5, Carol Hitchon6, Edward Keystone7, Carter Thorne8, Diane Tin9, Glen Hazlewood10 and Vivian Bykerk11, 1McGill University, Montreal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3University of Western Ontario, London, ON, Canada, 4Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10University of Calgary, Calgary, AB, Canada, 11Hospital for Special Surgery, New York, NY

    Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
  • « Previous Page
  • 1
  • …
  • 490
  • 491
  • 492
  • 493
  • 494
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology